Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus SATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus SATRIC.
CHLOROMYXIN vs SATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
No standard dosing information available for SATRIC.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
CHLOROMYXIN is not a recognized drug. No data available.
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Category C
Category C
Antibiotic
Antiprotozoal, Antibiotic